OK We use cookies to enhance your visit to our site and to bring you advertisements that might interest you. Read our Privacy and Cookies policies to find out more.

Business USA

PaloDEx has joined Gendex, DEXIS and ISI under the Danaher corporate umbrella.
Oct 23, 2009 | Business USA

Danaher acquires PaloDEx

by Fred Michmershuizen, DTA

NEW YORK, NY, USA: Danaher Corp. has entered into a definitive agreement to acquire PaloDEx Holding Oy (PaloDEx), a manufacturer of dental imaging products with revenues of more than US$100 million with products under the Instrumentarium Dental and SOREDEX brands. Instrumentarium Dental and SOREDEX will join Gendex, DEXIS, ISI, KaVo and Pelton & Crane as part of Danaher’s group of dental equipment companies.

Instrumentarium Dental and SOREDEX and their products have been highly regarded by dental professionals since their inception 45 years ago, according to a press release from Danaher announcing the acquisition. PaloDEx’s product range includes 3D CBCT, Panoramic X-ray (including the OP200), PSP (including the Optime IO PSP) and other intra-oral and extra-oral xray imaging systems.

“We believe this acquisition will be a game-changer for both of our companies, and we are excited about the opportunity to acquire two of the leading imaging brands,” said Henk van Duijnhoven, group executive of Danaher’s KaVo Group, in the release. “Instrumentarium Dental and Soredex’s excellent digital imaging products and technology will be a great fit with our existing Gendex, DEXIS and i-CAT business.”

“I am thrilled to join Danaher’s dental business,” said Henrik Roos, president of PaloDEx, who will remain in his position. “The combined business will create a unique opportunity to provide new and innovative technologies in digital dentistry with focus on diagnostics and treatment planning for general practitioners and specialists.”

“PaloDEx has a very experienced team, and we look forward to working with Henrik Roos and his team as we continue to build the business,” van Duijnhoven said.

Danaher’s transaction to acquire PaloDEx, announced on 12 October, is subject to regulatory approval and customary closing conditions.

Print  |  Send to a friend